Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
The present paper focuses on the different lines of evidence indicating that cannabinoid CB(1) receptor antagonists, including the prototype rimonabant, reduce food intake and body weight in laboratory animals. Recent clinical surveys demonstrated that rimonabant significantly reduced body weight also in overweight/obese humans. Treatment with rimonabant was associated with a beneficial effect on different metabolic parameters and cardiovascular risk factors linked to overweight. The data reviewed in this paper suggest that cannabinoid CB(1) receptor antagonists may constitute a novel class of drugs potentially effective in the treatment of obesity-related disorders.
Carai
Mauro A M
MA
C.N.R. Institute of Neuroscience, University of Cagliari, Cagliari (CA), Italy. macarai@unica.it
Colombo
Giancarlo
G
Maccioni
Paola
P
Gessa
Gian Luigi
GL
D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D004435:Eating / Q000187:drug effects*; D006801:Humans; D010601:Pharmacology, Clinical; D010880:Piperidines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant
D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant